Starting monthly extended‑release buprenorphine (XRB) when someone is booked into jail
Official title: Assessing Optimal Extended-Release Buprenorphine (XRB) Initiation Points in Jail
Run by NYU Langone Health · NCT06051890 · Data updated 2026-11-12
This project will try switching adults booked into jail who are already taking daily sublingual buprenorphine to a monthly injected buprenorphine at admission versus continuing daily sublingual, to see which helps people leave jail with ongoing buprenorphine and stay in treatment.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Sex | Men only |
| Enrollment | 50 (estimated) |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 4 sites (Boston, Massachusetts and 3 other locations) |
| Status | Recruiting |
| Started | June 2, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | March 1, 2027 |
| Registry record updated | August 7, 2026 |
| Trial ID | NCT06051890 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Unsentenced, English‑speaking adults entering participating jails who have been prescribed and taking sublingual buprenorphine for at least three days and who can provide informed consent are the intended participants.
✕Probably not a fit
People who are already sentenced, have allergies or medical contraindications to buprenorphine, require ongoing opioid pain management, or have very short expected stays (under four days) are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a 3‑year, randomized controlled trial enrolling 200 consenting, unsentenced adults entering participating jails who have been taking sublingual buprenorphine (SLB) for at least three days. Participants are randomized 1:1 at admission to be switched to extended‑release buprenorphine (XRB) while incarcerated or to continue SLB; all participants receive naloxone. Primary comparisons include the percent released from jail with at least seven days of buprenorphine in their system, the percent continuing medication for opioid use disorder (MOUD) in the community, and infractions related to buprenorphine diversion. The trial is led by NYU Langone Health with NIDA collaboration and is conducted at partnering sites including Middlesex County House of Corrections and affiliated health systems.
Why it matters
Potential benefit: If successful, initiating XRB at jail admission could help more people leave jail with continuous buprenorphine protection, increase treatment continuity after release, and reduce diversion-related problems.
How similar studies have gone: Extended‑release buprenorphine has shown improved retention over daily sublingual formulations in other trials, but initiating XRB specifically at jail admission has only limited prior pilot data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Incarcerated men able to provide written informed consent in English.\* * Unsentenced. * Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days. * Minimum anticipated jail stay is 4 days. * Willing to accept being randomized to the experimental condition (i.e., transitioning to XRB while incarcerated). Exclusion Criteria: * Sentenced. * Allergy, hypersensitivity or medical contraindication to either medication. * Chronic pain requiring opioid pain management or other contraindicated medications.
Where it's running
-
Tufts University Health Sciences
Boston, Massachusetts, United States Recruiting -
Baystate Health
Springfield, Massachusetts, United States Recruiting -
Middlesex County House of Corrections
New Brunswick, New Jersey, United States Recruiting -
NYU Langone Health - 180 Madison Ave
New York, New York, United States Recruiting
Study contacts
- Principal investigator: David Farabee, PhD — NYU Langone Health
- Study coordinator: David Farabee
- Email: David.farabee@nyulagone.org
- Phone: 310-963-0009
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CBD for Opioid Dependence and Pain on Buprenorphine
This study tests whether different doses of cannabidiol (CBD) can affect pain and opioid cravings in adults with opioid use disorder who are on buprenorphine, using a short, randomized, placebo-controlled setup.
-
Cebranopadol for opioid withdrawal in adults with chronic pain
This study tests whether cebranopadol can reduce withdrawal symptoms in adults with chronic pain who are physically dependent on prescribed opioids, compared with placebo.
-
emPath platform pilot to link and keep adults with opioid use disorder in care in Durham
This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.
-
CB1 Receptors in Opioid Use Disorder Measured with a PET Radioligand
This study tests CB1 receptor availability in people with opioid use disorder starting opioid agonist therapy and compares them with healthy adults.
-
STORC: Training a support person plus patient navigation after birth
We’re testing whether training a designated support person and using patient navigation after delivery helps people with opioid use disorder build recovery resources and stay in treatment.
-
Personalized Addiction Treatment Enhancement for Opioid Use Disorder
A digital platform run by peer recovery supporters will be tested to help adults with opioid use disorder who are on buprenorphine or methadone stay in treatment and improve outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.